This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
N2N Connect Bhd (June 28, RM1.24) Maintain buy with an unchanged fair value (FV) of RM1.50: During our meeting with N2N on Wednesday, management further detailed its plans with regard to a potential collaboration with SBI Holdings. One of the key considerations entails the development of a blockchain-enabled platform to digitise the trading of multiple financial instruments in one venue, including equities, derivatives and currencies.
0108 TRI SBHGF BSMAF 8473 1818
Designed to provide broad exposure to the Asia-Pacific (Developed) ETFs category of the U.S. equity market, the WisdomTree Japan SmallCap Dividend Fund (DFJ - Free Report) is a smart beta exchange traded fund launched on 06/16/2006.
DFJ EWJ DXJ SBHGF 8473 SZHFF
KUALA LUMPUR (June 14): Shares in N2N Connect Bhd rose as much as 4.06% to RM1.28 today — the highest in nearly 10 years — after Japanese financial services firm SBI Holdings Inc emerged as a substantial shareholder.
0108 SBHGF 8473
KUALA LUMPUR: AmInvestment Research has maintained its buy call on N2N Connect following its announcement of a proposed private placement with SBI Holdings Inc. Yesterday, N2N proposed a placement of about 52 million new ordinary shares of 10% of is total issued shares excluding treasury shares to the Japan-based finance company. "The issue price has been fixed at RM1.25/share, which represents a 13% premium to the 5-day VWAP – a testament to N2N’s deep value.
0108 9984 SFTBF SBHGF 8473 SFTBY
PETALING JAYA: It looks like N2N Connect Bhd ’s financial technology (fintech) strategy just got a bit more concrete. It has proposed to undertake a private placement of 10% or 52.04 million new N2N shares to Japan’s SBI Holdings at RM1.25 per placement share.
0108 SBHGF 8473
Yuzo Kano is trying to build a global cryptocurrency powerhouse, one former financier at a time.
BGX BCS.PRD BCS BCS.PRC BCS.PRA DGLD GS.PRB DTK GS.PRA BGLF CS MNXBF 83SF GS GLSSP UGLD 83SK ICE SBHGF 47MC JBK DSLV MNXBY VIIX GSC GS.PRICL CSSLF VIIZ TFG BX GSJ BGB GS.PRJ GS.PRI CSGKF BCS.PR GS.PRD GS.PRC ZIV USLV 8698 TVIX GS.PRN GJS 8473 GS.PRK XIV
Monex Group Inc CEO Oki Matsumoto (left) and Coincheck CEO Koichiro Wada attend a joint news conference in Tokyo, April 6, 2018. — Reuters picTOKYO, April 6 — Japanese online brokerage firm Monex Group Inc said today it would buy hacked cryptocurrency exchange Coincheck Inc, acquiring full ownership of the Tokyo-based firm for ¥3.6 billion (approx. RM130 million).
MNXBY 8698 SBHGF 8473 MNXBF
Japanese online brokerage firm Monex Group said on Friday it would buy hacked cryptocurrency exchange Coincheck, acquiring full ownership of the Tokyo-based firm for 3.6 billion yen ($33.59 million).
MNXBY 8698 SBHGF 8473 MNXBF
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
IBM UL UN UNLYF ULVR SBHGF UNLNF 8473
The Sri Lankan government this week invited Japanese investors to set up export-oriented industries in the upcoming industrial zones and offered Japan the opportunity to develop its own industrial zone in Sri Lanka.
15h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
17h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to SBHGF / SBI Holdings, Inc. on message board site Silicon Investor.
|Stock Watcheru0027s Thread / Pix of the Week (POW)|
as of ET